Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Positive Results in Arthritis Study

By Drug Discovery Trends Editor | August 1, 2012

A late-stage study of Pfizer Inc.’s experimental drug for moderate-to-severe rheumatoid arthritis found it worked better than the standard treatment.

Pfizer released limited results of the study, called ORAL Start, of its tofacitinib. It’s a new type of drug to fight the painful chronic inflammatory disorder, in which the immune system attacks the body’s joints, particularly the hands and feet.

The ongoing two-year study, sponsored by Pfizer, compared two doses of tofacitinib with methotrexate in 958 adults not previously treated with methotrexate. Data from a planned interim analysis found that after six months of treatment, the half of study participants getting tofacitinib had fewer signs and symptoms of the disorder, as well as less structural damage, than those getting methotrexate.

The study has not revealed any additional safety problems with tofacitinib. Research to date shows it can cause tuberculosis, herpes and other serious infections; lymphoma and other cancers; decreased levels of infection-fighting white blood cells called neutrophils; and elevated levels of lipids, or molecules in the blood that include cholesterol, fats and waxes.

Pfizer plans to submit a detailed analysis of the findings to a future medical conference.

Tofacitinib is being reviewed by regulators in the U.S., Europe and Japan. If approved, it would be the first rheumatoid arthritis treatment in a new class of medicines called Janus kinase or JAK inhibitors. The pill works by targeting pathways inside cells that function as hubs in the network of cytokines – messengers between cells that regulate inflammatory responses.

Pfizer noted the results during a conference call to review its second-quarter results. The New York-based company also said it plans in early August to submit a new analysis of tofacitinib data that the U.S. Food and Drug Administration requested. That will almost certainly push back the agency’s Aug. 21 target date for an approval decision.

FDA advisers in May voted 8-2 to recommend approval of the drug, but the agency later requested the data analysis.

Date: July 31, 2012
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE